Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360812 | 0.90 | IRAK4 (0.44) | MAPK14 | |
| SCHEMBL5352411 | 0.90 | GSK3B (0.45) | RIPK3NR3C2MAPK14GSK3B | |
| SCHEMBL5355784 | 0.90 | IRAK4 (0.42) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL5349670 | 0.89 | CDK9 (0.42) | RIPK3NR3C2MAPK14GSK3B | |
| SCHEMBL5349844 | 0.88 | TGFBR1 (0.40) | RIPK3NR3C2GSK3B | |
| SCHEMBL5354912 | 0.83 | MAPK14 (0.47) | NR3C2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28757702 | 0.82 | IRAK4 (0.40) | RIPK3GSK3B | |
| SCHEMBL27540546 | 0.82 | MAPK14 (0.59) | NR3C2MAPK14GSK3BCSNK1DMAPK13 | |
| SCHEMBL29974808 | 0.81 | NR3C2 (0.64) | RIPK3NR3C2MAPK14GSK3BCSNK1D | |
| SCHEMBL14143256 | 0.80 | MAPK14 (0.45) | MAPK14CSNK1DMAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-100519552-C | Pyrazole compounds | UBE INDUSTRIES (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| CN-1684953-A | Pyrazole compounds | UBE INDUSTRIES (JP) | 2005-10-19 | — | — | CN | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | RIPK3 244/4885NR3C2 480/4885MAPK14 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.